CD8A and ovarian cancer: - AZD5153 enhances antitumor immunity by repolarizing TAMs to an M1-like phenotype.- Downregulates PD-L1 on TAMs, sensitizing ovarian cancer cells to anti-PD-L1 therapy.- Promotes activation of CD8+ cytotoxic T cells, offering a potential combination strategy with immune checkpoint inhibitors for treating ovarian cancer.